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Abbreviations
6MWT  6-minute walk test
6MWD  6-minute walk distance
HR  Heart rate
LVDd%N  Left ventricular diastolic dimension—per-
centage of mean value for body surface area
NTproBNP  N-terminal pro-brain natriuretic peptide
PAH  Pulmonary arterial hypertension
∆RV/RA  Systolic gradient right ventricle-right atrium
SAT  Blood oxygen saturation
WHO-FC  WHO functional class
Introduction
6-minute walk test (6MWT) is a submaximal exercise test 
applied for evaluation of adults with pulmonary arterial 
hypertension (PAH) [1]. It was widely used as an endpoint 
in the clinical studies [2]. According to European Society 
of Cardiology guidelines (2015 [1] and previous), distance 
reached in 6MWT (6MWD) is one of the factors in risk 
assessment in pulmonary arterial hypertension. In children, 
6MWD is not used as a prognostic parameter [3] due to the 
difficult cooperation, dependence on age, height, and gen-
der. However, it remains the only exercise test easy to per-
form and accepted by children with exercise limitations [4].
The aim of this study was to assess the usefulness of 
6MWT for evaluation of children with pulmonary arterial 
hypertension and to establish correlations with other clini-
cal features.
Abstract Six-minute walk test (6MWT) is a submaxi-
mal exercise test applied for evaluation of adults with pul-
monary arterial hypertension (PAH). It was widely used 
as an endpoint in the clinical trials. The aim of the study 
was to assess the usefulness of 6MWT in management 
of children with PAH and to establish correlations with 
other clinical features. 164 6MWT were performed in 15 
children between 5 and 18 years with PAH confirmed by 
right heart catheterization (102 in patients with shunt, 62 
without shunt). Distance in 6MWT (6MWD)—% of pre-
dicted for age and gender, desaturation at the maximum 
effort, peak heart rate (HR)—% of maximal HR, were 
compared to the level of NTproBNP, WHO-FC, echocar-
diography parameters, and events of PAH treatment inten-
sification. 6MWD had low negative correlation with peak 
HR (τ −0.1 p = 0,03), negative correlation with NTproBNP 
(τ −0.17 p = 0.002), and no dependence on echocardiog-
raphy parameters. The presence of shunt was associated 
with lower 6MWD, lower blood saturation at rest, and 
higher desaturation after effort. Patients in III/IV WHO-FC 
achieved higher rest HR and maximal HR in comparison 
to patients in I/II WHO-FC (63.1 vs. 55.2% p < 0.01) and 
lower 6MWD (64.3 vs. 77.5% p < 0.01). In 14 out of 20 
6MWT performed after treatment intensification, increase 
of distance was observed. The results of 6MWT were con-
sistent with clinical status (WHO-FC, NTproBNP) but not 
with echocardiography parameters. 6MWT may be the 
source of additional information in management of children 
with PAH.
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Analysis includes 164 6  MW tests performed every 3 
months in 15 children with PAH confirmed in right heart 
catheterization. The number of tests per 1 patient ranged 
from 1 to 23 (mean 11 ± 7, median 9). The age during the 
test was 5–18 years (mean 13.4 ± 4.0; median 14.8), and 
there were no patients with Down syndrome and physi-
cal or mental disability. Distribution of tests performed 
in patients in I/II WHO functional class (WHO-FC) and 
III/IV WHO-FC was 129 to 35. 102 tests were done in 
patients with shunt—multiple ventricular septal defects, 
atrial septal defect ostium secundum, partial anomalous 
pulmonary venous drainage, tricuspid atresia, atrio-ven-
tricular septal defect, idiopathic PAH after Potts shunt, 
and 62 in children without shunt—idiopathic PAH, post-
operative congenital heart defect (Table  1). All patients 
had no bradycardia in 24-h Holter electrocardiography 
monitoring performed before 6MWT. The 6MWT were 
performed according to American Thoracic Society 
standard [5]. Distance, blood oxygen saturation before 
test (rest SAT) and desaturation at the maximum effort 
(rest SAT–SAT 6′), initial and maximal heart rate (rest 
HR, peak HR) were analyzed. Distance was shown as 
percentage of predicted for age and gender. Normal value 
of distance was calculated using gender-specific, age-
adjusted reference equations [6] (Table 2). Heart rate was 
analyzed as percentage of median for age [7] (rest HR) 
and percentage of maximal heart rate for age (220-age)—
peak HR. Submaximal exercise was defined as reaching 
no more than 85% of maximal heart rate [8]. Addition-
ally ratio peak heart rate (% of max HR) to distance (% of 
predicted) was calculated. Obtained data were compared 
with the WHO-FC, level of N-terminal pro-brain natriu-
retic peptide (NTproBNP), echocardiographic param-
eters: left ventricular diastolic dimension—percentage 
of mean value for body surface area (LVDd%N), systolic 
gradient right ventricle-right atrium (∆RV/RA) (Table 3), 
and events of PAH treatment intensification (first admin-
istration, uptitration, or addition of new PAH-specific 
drug; Potts shunt) (Fig. 1). In order to determine the rela-
tionship between distance and clinical parameters, 6 MW 
tests were divided for three groups: with good, medium, 
and poor results according to percent of predicted dis-
tance (PPD >80%, 60–80%, and <60%) (Table 4).
 Procedures analyzed in this study are the part of 
standard care of patients with pulmonary hypertension. 
All are required by the National Health Fund to reim-
bursement of pharmacotherapy. Informed consent to par-
ticipate in the therapeutic program of the National Health 
Fund was obtained in all patients.
Statistical Analysis
Continuous data were presented as values with an average, 
a standard deviation, and a median. Normal distribution 
was determined using Shapiro–Wilk test. To compare of 
distribution in groups, parametric (T-student) and non-par-
ametric (Whitney–Mann) tests were used. The limit for sta-
tistical significance was set at p < 0.05. Obtained data were 
shown on the boxplot. Differences among three groups 
of tests (good, medium, poor result) were analyzed using 
analysis of variance (ANOVA). To measure the association 
between two measured quantities, Kendall’s rank correla-
tion coefficient (tau) was used.
Results
 In all tests, reached distance adjusted to age and gen-
der ranged from 22 to 109% of predicted value (mean 
74.3 ± 12.6%; median 76.5%). 11 patients in 51 tests 
reached distance more than 80% predicted (good result 
group). In this group, a lower WHO-FC (92% WHO-FC 
I/II) and a lower level of NTproBNP (431.1 ± 762.2) were 
found. 55% of tests were performed by patients with PAH 
without shunt therefore with higher saturation, and lower 
mean desaturation. 7 patients in 20 tests did not achieve 
60% PPD (poor result group). Mean age during tests 
was lower than in other groups. 75% tests in this group 
were performed by patients with shunt therefore the rest 
saturation was lower. Patients were in higher WHO-FC 
(80% WHO-FC III/IV), with higher level of NTproBNP 
(3108.5 ± 2495.4), rest HR, and peak HR despite the 
increase heart rate (ΔHR) was lower. There were no dif-
ferences in echocardiography parameters irrespectively of 
6MWT results (good, medium, and poor).
In whole material, the walk distance had low nega-
tive correlation with peak heart rate (τ −0.1 p = 0.03) 
(Fig. 2) and negative correlation with NTproBNP (τ −0.17 
p = 0.002) (Fig.  3). No dependence on echocardiography 
parameters was found. All results of 6MWT are shown in 
(Table 4).
20 events of treatment intensification were detected in 
11 patients (Fig. 1). In 17 cases, it was associated with at 
least 5% change of distance in the next 6MWT (after 1–3 
months). Increase in percentage of predicted value (7–25%, 
mean 13 ± 6, median 10.5%) was observed in 14 events in 
10 patients. In 3 patients, the percentage of predicted value 
decreased by 6–25%. In those cases further intensification 
of treatment was taken: dose escalation with good results 


































































































































































































































































































































































































































































































































































































































































































































































































































































Shunt Versus No Shunt (Table 3)
The percentage of patients in WHO-FC III/IV was similar 
in both groups (shunt 27.2%; no shunt 22.5%). Walk dis-
tance in patients with shunt was lower than without shunt 
(73 vs. 77% p = 0.02) (Fig. 4). No differences in heart rate 
(initial and peak) were observed. The presence of shunt 
was associated with lower blood saturation at rest (90 vs. 
98% p < 0.01) (Fig. 5) and higher desaturation after effort 
(17.5%HbO2 vs. 3%HbO2 p < 0.01) (Fig. 6).
WHO III/IV Versus I/II (Table 3)
The percentage of patients with shunt was similar in both 
groups (III/IV 57.5%; I/II 63.7%). Patients in III/IV WHO-
FC achieved significantly lower walk distance than children 
with I/II WHO-FC (64.3 vs. 77.5% p < 0.01) (Fig. 7). They 
had higher rest HR (113 vs. 97% of normal value p < 0.01) 
(Fig.  8), similar increase of HR during effort (38 vs. 39 
beats NS), and higher peak HR (63.1 vs. 55.2% of maximal 
heart rate for age p < 0.01) (Fig. 9). Only in six tests criteria 
of submaximal exercise was exceeded or was only slightly 
below limit (81–84%). Five of them were performed by 
patients in III WHO-FC with the average distance 69 vs. 
74% in the rest of the tests (too small group for statistical 
analysis). Peak heart rate-to-distance ratio in patients with 
III/IV WHO-FC was significantly higher than in patients in 
I/II WHO-FC (1.1 vs. 0.7 p < 0.01) (Fig. 10).
Discussion
This study demonstrated that the results of 6MWT in chil-
dren with pulmonary hypertension are associated with 
clinical status, especially with WHO-FC and NTproBNP 
which are unquestioned prognostic factors in this disease 
[3]. No dependence on echocardiography parameters was 
detected, but only basic measurements were included. 
Similarly Placido et al. [9] reported no correlation between 
conventional parameters of the RV function and 6 MWD in 
adults with pulmonary arterial hypertension. It is possible 
that more detail examination of systolic and diastolic func-
tion in echo using advanced methods will be more useful to 
detect correlation between echo and 6MWD and this needs 
further investigation, especially in children.
The usefulness of the 6MWT was confirmed in many 
studies in adults [10–12], so in ESC guidelines 2015 [1] 
Table 2  Equations to predict 




 <13 yo 24.18 × y + 385.18
 >13 yo 13.08 × y + 476.69
Girls
 <12 yo 20.83 × y + 413.94
 >12 yo −8.66 × y + 757.42
Table 3  Results of all analyzed 6MWT (data presented as mean ± SD and median)
Bold values indicate statistically significant (p < 0.05)
Parameters Units All 6MWT Shunt No shunt p WHO-FC I/II WHO-FC III/IV p
N 164 102 62 124 40
















































































































Fig. 1  Change of 6MWD after treatment intensification (PPD—% of 
predicted distance for age and gender)
Table 4  6MWTs divided into groups: good, medium and poor result (data presented as mean ± SD)
Abbreviations description in the text
Group All
N = 164












Mean PPD 48.1 ± 10.1%
p
Clinical data
 Shunt 102 (62%) 23 (45%) 64 (69%) 15 (75%) <0.01
 Age (years) 13.4 ± 4.0 14.7 ± 3.4 13.5 ± 3.6 9.4 ± 4.6 <0.01
 WHO-FC 2.2 1.9 2.2 2.9 <0.01
 Rest HR 80.0 ± 17.7 77.2 ± 14.2 75.9 ± 13.6 106.3 ± 20.7 <0.01
 Rest SAT (%HbO2) 92.6 ± 6.3 93.9 ± 5.7 92.8 ± 5.9 88.9 ± 8.2 <0.01
 NTproBNP (pg/ml) 899.9 ± 1946.9 431.1 ± 762.2 666.9 ± 1952.8 3108.5 ± 2495.4 <0.01
Echo
 LVDd%N 90.8 ± 11.5 89.5 ± 9.9 91.4 ± 12.3 90.8 ± 11.6 NS
 ΔRV-RA 94.7 ± 24.7 88.7 ± 26.9 96.6 ± 25.4 96.2 ± 19.3 NS
6MWT
 Peak HR 117.9 ± 24.4 114.0 ± 23.3 117.2 ± 25.0 131.4 ± 20.5 0.02
 HR% max 57.1 ± 11.9% 55.6 ± 11.4% 56.8 ± 12.4% 62.5 ± 10.0% NS
 ΔHR 38.6 ± 25.1 36.8 ± 24.0 42.3 ± 24.1 25.5 ± 28.5 0.02
 Peak SAT (%HbO2) 80.7 ± 14.6 85.5 ± 13.7 78.4 ± 14.5 78.7 ± 14.6 0.01
 Desaturation (%HbO2) 11.8 ± 11 7.8 ± 9.7 14.4 ± 11.7 10.2 ± 9.5 <0.01
Fig. 2  Correlation between 6MWD and peak heart rate (peak HR)
Fig. 3  Correlation between 6MWD and NTproBNP level
Fig. 4  6MWD in patients with shunt and no shunt
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and previous, 6MWD is recommended as one of prognosis 
determinants. There are many doubts regarding the useful-
ness of 6MWT in children because the results depend on 
age, gender, and developmental parameters. Additionally, 
reproducibility of this test in children depends on proper 
cooperation, which is not always possible. In our study, we 
use percentage of normal value adjusted for age and gender 
to eliminate developmental differences. Martins et al. [13] 
have verified the reproducibility of the 6-min walk test 
in healthy children at the age of 6–14 years. No effect of 
learning on the distance in second test was observed. 
Similar results were obtained by Morinder et al [14], who 
Fig. 5  Blood saturation at rest (rest SAT) in patients with shunt and 
with no shunt
Fig. 6  Desaturation after effort in patients with shunt and with no 
shunt
Fig. 7  6MWD in patients in I/II WHO-FC in comparison to patients 
in III/IV WHO-FC
Fig. 8  Rest heart rate (rest HR) in patients in I/II WHO-FC in com-
parison to patients in III/IV WHO-FC
Fig. 9  Peak heart rate (peak HR) in patients in I/II WHO-FC in com-
parison to patients in III/IV WHO-FC
Fig. 10  Peak heart rate (peak HR) to 6MWD ratio in patients in I/II 
WHO-FC in comparison to patients in III/IV WHO-FC
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examined a group of 49 obese and 97 healthy children. 
Taking into account the above evidence, analysis of the 
individual tests (not individual patients) seems reasonable 
and should not be fraught with bias resulting from age and 
the effect of learning.
Many authors evaluated the results of 6MWT in children 
with chronic diseases (for example, pulmonary diseases 
[15], obesities [14], connective tissue diseases, and hemato-
logical and neurological abnormalities [16]). In most stud-
ies, 6MWT was recognized as a useful in the evaluation of 
chronically ill children. However, standards of performance 
of 6MWT are different, so comparison between studies is 
difficult and conclusion should be interpreted with caution 
[17].
There are limited data concerning the usefulness of 
6MWT in children with PAH.
Based on recent studies, where baseline 6MWD was not 
a predictor of survival in children with pulmonary hyper-
tension, Ivy et  al. [18] concluded that 6MWT should not 
be consider in risk assessment in PAH children in contrast 
to adults. However, the results of other studies suggest that 
6MWT can be useful in the management of pediatric PAH. 
Lammers et  al. [19] published data of 47 children with 
PAH at the mean age of 11.4 years, where 6 MW distance 
in single measurement was one of the predictors of death 
or need for transplantation. The same author [20] evaluated 
results of 6MWT in PAH children. In this study, 6MWD 
was significantly shorter than predicted (47.7 ± 16.7%). 
6MWT was a submaximal test in most of patients. Heart 
rate limit for maximal effort was reached only by children 
with a 6MWT distance of less than 300  m. That is com-
patible with our observation—distance in all tests was less 
than predicted, and criteria of submaximal effort exceeded 
patients with WHO-FC III/IV with shorter 6MWD.
We observed shorter 6MWD in PAH patients with shunt 
compare to patients with IPAH or PAH after shunt closure. 
The same results, but without statistical significance, were 
published by Lammers [20] and Douwes [21]. Additionally, 
Lammers demonstrated lower exercise capacity measured 
in CPET in patients with Eisenmenger syndrome compare 
to patient after shunt closure. As explained by Dimopou-
los [22], it may be abnormal ventilatory response to exer-
cise due to cyanosis. In the presented material, patients 
with Eisenmenger syndrome characterized by ventilation to 
perfusion mismatch. They have lower peak oxygen uptake 
(VO2max) and significantly higher ventilation per unit of 
CO2 production (VE/VCO2) slope, and lower expiratory 
exchange ratio at peak exercise.
Study published by Douwes [21] contains two issues—
evaluation of 6MWT as a prognostic factor and as a deter-
minant of disease severity. 6MWD was negatively cor-
related with NTproBNP and WHO-FC (similarly to our 
results and Van Albada study [23]). Patients with shunt 
had higher desaturation on the peak of effort. No correla-
tion between heart rate and WHO-FC was observed. On the 
contrary, our study showed higher heart rate during 6MWT, 
baseline and maximal, in patients in III/IV WHO-FC. The 
results of both studies (Douwes’ and ours) conducted using 
different methods indicate that 6MWT may be useful in 
monitoring of disease severity.
Study Limitation
We analyzed the tests independently which were repeated 
several times by the same patients, however, in different 
clinical conditions. The study group does not have limita-
tions associated with the physical development or intel-
lectual disability or pathology of other systems. The bias 
related to age and the effect of learning seems to be irrele-
vant of the reasons mentioned above. However, the individ-
ual differences in exercise capacity of patients may affect 
the results. On the other hand, the studies assessing 1 test in 
each patient do not take into account the changes of clinical 
status and treatment. Thus, the predictive value of identical 
result of the test in child before treatment vs child receiving 
the combination therapy is different. Therefore it would be 
rational to apply advanced statistical modeling methods in 
a larger group of patients who have performed many tests 
to achieve more satisfactory results.
Conclusions
The results of the 6MWT in children with pulmonary 
hypertension reflect clinical status (WHO-FC, NTproBNP), 
but not echocardiography parameters. 6MWT may be the 
source of additional information in assessment and man-
agement of children with PAH. 6MWT repeated in routine 
control may be helpful in treatment decisions.
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